Notice of US patent allowance
Notice of US patent allowance for Medherant’s testosterone patch for post-menopausal women 6 September 2024 (Coventry, UK). Medherant is pleased to announce that it has received the notice of allowance from the US Patent and Trademark Office for...
Preliminary results of clinical study of Medherant’s testosterone patch for post-menopausal women
10 April 2024 (Coventry, UK). Medherant is pleased to announce the preliminary results of the Phase I study of its testosterone patch technology being conducted at Hammersmith Medicines Research (HMR; London). Preliminary results from this study demo...
Medherant transdermal patch development collaboration with Bayer
Coventry, UK (25 March 2024): Medherant Limited (“Medherant”) announces that it has entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine...
Happy World Menopause Awareness Day!
At Medherant, we're committed to empowering women through knowledge and innovative solutions for managing menopause. Did you know that peri-menopause and menopause affects over 13 million women in the UK? At Medherant, we're committed to raising a...
Start of dosing in clinical study of Medherant’s testosterone patch for post-menopausal women
13 October 2023 (Coventry, UK). Medherant is pleased to announce that the Phase I study of its testosterone patch for post-menopausal women has been initiated at Hammersmith Medicines Research (HMR; London). The first group of volunteers has been ...
Approval of Clinical Trial Application for Phase I study of Medherant’s testosterone patch for post-menopausal women
2 October 2023 (Coventry, UK). Medherant is pleased to announce that approval has been received from MHRA and the Research Ethics Committee for the Clinical Trial Application for a Phase I study in healthy post-menopausal women of Medherant’s testo...
Medherant New Appointments (September 2023)
Medherant appoints Karolina Afors as Medical Director and Fran Crawford joins as a non-executive director 11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created ...
Medherant secures further funding for development of testosterone patch for post-menopausal women
3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management. Medherant will principally use the funding to progress development of a testosterone tr...
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology
Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients Cambridge & Coventry, UK – 5 May 2020 – Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (M...
Medherant named as one of the 50 most innovative businesses in the Midlands
Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, is excited to announce it has been selected as one of the 50 m...